abrdn plc Has $934,000 Holdings in Repligen Co. (NASDAQ:RGEN)

abrdn plc boosted its stake in Repligen Co. (NASDAQ:RGEN) by 1.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,192 shares of the biotechnology company’s stock after buying an additional 71 shares during the quarter. abrdn plc’s holdings in Repligen were worth $934,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. DekaBank Deutsche Girozentrale lifted its holdings in Repligen by 1.5% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock valued at $1,663,000 after purchasing an additional 159 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in shares of Repligen by 18,449.1% in the 4th quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock worth $10,539,000 after acquiring an additional 58,299 shares in the last quarter. American Century Companies Inc. grew its position in Repligen by 97.5% during the 3rd quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock worth $34,648,000 after acquiring an additional 107,570 shares during the last quarter. Louisiana State Employees Retirement System bought a new position in Repligen in the 4th quarter valued at $2,625,000. Finally, Atria Investments Inc acquired a new position in Repligen in the third quarter worth $1,046,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Price Performance

Repligen stock opened at $166.14 on Tuesday. The firm has a market capitalization of $9.28 billion, a P/E ratio of 230.75, a PEG ratio of 5.46 and a beta of 1.02. The business has a 50-day moving average of $183.37 and a 200-day moving average of $173.88. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million for the quarter, compared to analysts’ expectations of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The business’s quarterly revenue was down 16.6% compared to the same quarter last year. During the same period last year, the firm posted $0.68 earnings per share. On average, equities analysts anticipate that Repligen Co. will post 1.46 EPS for the current year.

Insider Activity

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Karen A. Dawes sold 1,000 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the sale, the director now directly owns 87,367 shares in the company, valued at $16,892,409.45. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock worth $5,039,532 in the last 90 days. Corporate insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. KeyCorp increased their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Stifel Nicolaus increased their price target on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $196.70.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.